UM E-Theses Collection (澳門大學電子學位論文庫)
Title
新藥研發國際化佈局與網路 : 基於2000-2009年美國上市NME 新藥專利的實證研究
English Abstract
Backgroud With the acceleration of economic globalization and international competition became more intense, multinational corporations began to focus on the comparative advantage of talent, technology strength and research infrastructure in worldwide, to find out the best zone to locate R&D, promting globalization of their R&D activities. With globalization evolution of overall R&D process in pharmaceutical industry, multinational corporations constructed a great deal of R&D cooperation in developing countries. It is important to development of R&D internationalization in pharmaceutical industry in China to study how the countries integration resources and strengthen regional cooperation in R&D international cooperative network in order to improve their competition strength of pharmaceutical industry. The objective is to analyze the characteristics of localization and cooperative network of new drug’s international R&D, then make recommendations to China according to its actual conditions. ion data of approve NME drugs between Jan 2000 and Dec 2009 in Drugs@FDA database. Collection information of their core patents in IMS health database. Retrieving American patents in patent family of NME drugs in Derwent database. Retrieving relative information (name and geographic information) of patent inventors and patentees of relative American patents in USPTO database. Conducting analysis(statistical analysis and social network analysis,HHI index to analyze R&D density). Results The US is still the core and North America, Western Europe and Japan trigonal rigions are still the key location and key R&D output source in international R&D of pharmaceutical industry. In internalional cooperative network of R&D, The US has the largest authority, is the international center of the network, Japan is the center of the Asian network, and Germany is the center of Western Europe. The concentration of pharmaceutical R&D is high and most R&D cooperation is limited in one country. China is still relatively marginal in the international cooperation network of R&D. Conclusion The concentration of pharmaceutical R&D is high, geographic distance factor still has enormous impact on R&D activities. the status of the three polarization in international R&D cooperation has not been broken, the trigonal rigions are still the main carrier of pharmaceutical R&D. Localization and network of international pharmaceutical R&D are affected by multiple factors, such as one-up resource, cutting-edge technology and policy environment. China already has the technological strength and wilingness to take part in international pharmaceutical R&D, with cost advantage that deveoped countries do not have, China could establish R&D strategic alliance with Japan or other emerging market countries to participate international R&D cooperative network more deeply and enhance its influence and power in the network. Keyword internationalization, R&D cooperation, cooperative network, geographic localization
Chinese Abstract
背景:隨著經濟全球化進程的加速和國際競爭的日趨白熱化,跨國公司的研發開始著眼 於世界範圍內人才、科技實力與科研基礎設施的比較優勢,尋找研發配置的最佳區位元, 從而促使跨國公司的 R&D 活動日益朝著全球化方向發展。隨著醫藥行業總體研發流程 的全球化演變,醫藥跨國企業在國際上整合研發資源的趨勢越演越烈,在發展中國家開 展了大量的合作,探討各國在研發國際化中如何根據自身的實力整合資源,發揮各自的 比較優勢,加強區域合作,以提高國家的醫藥發展的競爭力對中國醫藥行業研發國際化 有重要的參考意義。本文的目的在于通過描述醫藥行業研發國際化佈局和網路的狀況, 分析醫藥研發網路和佈局的特點,并结合中国的情况提出建议。 方法:使用 Drugs@FDA 資料庫進行檢索,收集 2000 年 1 月至 2009 年 12 月 FDA 批准 的 1 類新藥申請的藥物通用名資訊,在 IMS health 資料庫裡檢索藥物核心專利資訊,並依此 在 Derwent 專利資料庫中檢索 NME 新藥的專利家族資料,並從中提取出美國專利,最後 在 USPTO 專利資料庫中檢索美國專利相關資訊,提取發明人及專利權人的姓名和地理資 訊、註冊時間資訊。對這些資訊進行統計整理,分析醫藥行業核心研發國際化的佈局, 並使用網路理論和 HHI 指數對其國際化合作網路進行描述與分析。 結果:在醫藥行業研發國際化的佈局中,美國依然是主體,北美、西歐、日本三極化區 域依舊是研發的關鍵位置與主要產出來源。在醫藥行業研發國際化的合作網路中,美國 擁有最大的權威,是國際化研發合作網路的中心,而日本是亞洲研發合作網路的中心, 德國是西歐研發合作網路的中心。醫藥行業的研發集中程度很高,而且大部分研發都是在 國內進行合作。中國在醫藥研發國際化網路中的地位依舊比較邊緣。 結論:醫藥行業的研發集中程度很高,地理距離因素依舊對研發產生巨大的影響。醫藥 行業研發中的三極化的狀況沒有得到破除,三極化地區依然是醫藥研發的主要載體,醫 藥行業研發的佈局和網路構建受到多重因素影響,但其研發對領先資源、前沿科技和政 策環境因素更加敏感。三極化區域的領先資源、前沿科技和政策環境促使本土醫藥行業 的技術實力的提升,吸引了國際跨國公司到此進行研發投資,而大量的外國投資又進一 步增強三極化區域的研發實力。對於醫藥研發國際化,中國已經具有了相應的科技實力 和參與意願,而且具有發達國家不具有的成本優勢,中國可以通過與日本或者其他新興 市場國家建立研發戰略聯盟,更深入的參與到國際化研發中,增強其在國際化網路中的影響力和權力。 關鍵字:國際化、研發合作、合作網路、地理佈局
Issue Date
2011
Author
張時開
Faculty
Institute of Chinese Medical Sciences
Degree
M.Sc.
Subject
Medicinal Administration -- Institute of Chinese Medical Sciences
醫藥管理 -- 中華醫藥研究院
Patent medicines -- China
專利權藥物 -- 中國
Pharmaceutical industry -- Economic aspects
藥業 -- 經濟方面
Supervisor
王一濤
Library URL
b2525087
Files In This Item:
TOC & Abstract
Full-text
Location
1/F Zone C
Supervisor
--